Novartis brings leprosy antibiotic Lamprene back to US commercial market
Novartis received supplemental FDA approval for Lamprene over the summer. The decades-old leprosy treatment is now moving to the commercial market in the US, which could improve access.
Expanded Detail
...
Expanded detail and Context are AI-generated analysis; the linked article remains the authoritative source.
Related stories
Monthly Injectable Olanzapine Approved for Schizophrenia · Mental health
This summary is Al-enhanced to contain extended analysis and broader social context. The original is {NAME); the linked article is the authoritative source. Original headline: “Novartis quietly returns a key antibiotic to US market.” Browse more stories.